Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: Effect on nerve function

Green, 1988, Pathogenesis and prevention of diabetic neuropathy, Diabetes Metab Rev, 4, 201, 10.1002/dmr.5610040303

Ward, 1972, Effect of blood sugar control on the accumulation of sorbitol and fructose in nervous tissue, Diabetes, 21, 1173, 10.2337/diab.21.12.1173

Masson, 1990, Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence, Drugs, 39, 190, 10.2165/00003495-199039020-00003

Judzewitsch, 1983, Aldose reductase inhibition improves nerve conduction velocity in diabetic patients, N Engl J Med, 308, 119, 10.1056/NEJM198301203080302

Martyn, 1987, Six-month treatment with sorbinil in asymptomatic diabetic neuropathy: Failure to improve abnormal nerve function, Diabetes, 36, 987, 10.2337/diabetes.36.9.987

Dyck, 1980, Human diabetic endoneural sorbitol, fructose, and myoinositol related to sural nerve morphometry, Ann Neurol, 8, 590, 10.1002/ana.410080608

Dyck, 1988, Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy, N Engl J Med, 319, 542, 10.1056/NEJM198809013190904

Sima, 1988, Regeneration and repair of mylenated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil, N Engl J Med, 319, 548, 10.1056/NEJM198809013190905

Sima, 1988, Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysfunction in human diabetic neuropathy, J Clin Invest, 81, 349, 10.1172/JCI113327

Britland, 1990, Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration, Diabetes, 39, 898, 10.2337/diabetes.39.8.898

Dyck, 1984, Diagnosis, staging, and classification of diabetic neuropathy and associations with other complications, 36

Dyck, 1985, Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy, Brain, 108, 861, 10.1093/brain/108.4.861

Dyck, 1989, Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy, Diabetes Care, 12, 649, 10.2337/diacare.12.9.649

Greene, 1990, Biochemical and morphometric response to tolrestat in human diabetic nerve [Abstract], Diabetologia, 33, A92

Greene, 1991, Aldose reductase inhibitor treatment normalizes axo-glial dysjunction and improves nerve fiber pathology in advanced diabetic neuropathy [Abstract], Diabetes, 40, 9A

Macleod, 1991, The effect of the aldose reductase inhibitor tolrestat on diabetic polyneuropathy: A meta-analysis [Abstract], Diabetes, 40, 555A

O'Brien, 1984, Procedures for comparing samples with multiple endpoints, Biometrics, 40, 1079, 10.2307/2531158

Fagius, 1981, Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy—A clinical and neurophysical study, J Neurol Neurosurg Psychiatry, 44, 991, 10.1136/jnnp.44.11.991

Veves, 1991, The relationship between sural nerve morphometric findings and measures of peripheral nerve function in mild diabetic neuropathy, Diabetic Med, 8, 917, 10.1111/j.1464-5491.1991.tb01530.x